Previsioni

Il prezzo obiettivo medio degli analisti è +34,35€ (+8,02%). La mediana è +35,21€ (+10,72%).

Acquista	14
Mantieni	1
Vendi	0

Notizie Vai al feed delle notizie

Roivant Sciences shares reach record high at $37.06

Roivant Sciences shares rose to an all-time high of $37.06 and are currently trading at $37.14, with a market capitalization of $26.19 billion. The stock has gained 206.52% over 12 months and 66.82% year-to-date; however, analysts view the stock as overvalued according to InvestingPro. In the first fiscal quarter, adjusted loss per share was $0.26 (better than the expected -$0.30), but revenue of $1.44 million fell short of forecasts. TD Cowen raised its price target from $41 to $50 and reiterated a "Buy" rating, citing potential catalysts in the second half of the year. » Altro su de.investing.com
Roivant Sciences: investment three years ago would have returned about 195%

Three years ago Roivant Sciences traded at $11.50. A $10,000 investment would now be worth about $29,487 at a share price of $33.91, an increase of 194.87%. The company is valued at roughly $24.50 billion on the market; calculation does not account for stock splits or dividends. » Altro su finanzen.net
Roivant Sciences: $10,000 investment five years ago now up 262.97%

A $10,000 investment in Roivant Sciences at the closing price on 13 July 2021 ($9.91) would have grown to $36,296.67 by 10 July 2026, based on a price of $35.97 per share and a performance of +262.97%. The company is recently reported to have a market capitalization of $25.92 billion. The calculation does not account for stock splits or dividends. » Altro su finanzen.net

Dati finanziari dell'azienda

Nell'ultimo trimestre, Roivant Sciences ha registrato ricavi pari a 1,26 Mio€ e un utile netto di −166,33 Mio€

(EUR)	giu 2026	YoY
Ricavi	+1,26 Mio	31,37%
Utile lordo	+1,01 Mio	40,68%
Utile netto	−166,33 Mio	12,23%
EBITDA	−252,59 Mio	11,02%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+22,60 Mrd€
Numero di azioni	722,41 Mio
Massimo/minimo a 52 settimane	+32,60€ - +9,98€
Dividendi	No
Beta	1,13
Rapporto P/E	−95,88
Rapporto PEG	+0,80
Rapporto P/B	+6,21
Rapporto P/S	+3.494,54

Profilo aziendale

Roivant Sciences Ltd. ist ein biopharmazeutisches und medizintechnisches Unternehmen, das Medikamente erforscht und entwickelt. Das Unternehmen entwickelt Produktkandidaten für die Behandlung verschiedener Therapeutika, darunter solide Tumore, Sichelzellerkrankungen, Hypophosphatasie, onkologische Malignome, Psoriasis, atopische Dermatitis, Vitiligo, Hyperhidrose, Akne, Myasthenia gravis, warme autoimmune hämolytische Anämie, Schilddrüsenerkrankungen, Sarkoidose und Staphylokokkenbakteriämie. Das Unternehmen wurde im Jahr 2014 gegründet und hat seinen Sitz in London, Vereinigtes Königreich.

Nome	Roivant Sciences
CEO	Matthew Gline
Sede centrale	London, gl Stati Uniti
Sito web	roivant.com
Settore	Sanità
Industria	Prodotti farmaceutici
Quotazione in borsa	08/12/2020
Dipendenti	721